Abstract
Purpose/Objective: NSCLC commonly overexpresses EGFR (epidermal growth factor receptor) and preclinical model systems demonstrate radiosensitization following molecular inhibition of EGFR signaling. Gefitinib (Iressa) is a small molecule selective EGFR tyrosine kinase inhibitor. HRT allows for a shorter RT course and a potentially improved local tumor control. We report toxicity in an ongoing Phase I trial of gefitinib and dose-escalated HRT in patients (pts) with advanced NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
